AWM
CRSP icon

Avitas Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Avitas Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-16,350
Closed -$1.99M – 203
2021
Q1 		$1.99M Sell
16,350
-4,544
-22% -$686K 0.39% 97
2020
Q4 		$3.2M Buy
+20,894
New +$2.47M 0.65% 50

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Avitas Wealth Management's CRSP Position: Q2 2021 in Review

Avitas Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q2 2021, closing a stake of 16,350 shares — an estimated $1.99M sold.

Avitas Wealth Management first reported a position in CRSP in Q4 2020 and held it in 2 quarters. The position peaked at $3.2M in Q4 2020. 498 funds tracked by Wall St. Rank hold CRSP as of Q2 2021.

  • Avitas Wealth Management reported no remaining CRISPR Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Avitas Wealth Management sold 16,350 CRISPR Therapeutics shares in Q2 2021, an estimated $1.99M.
  • Avitas Wealth Management first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 2 quarters.
  • Avitas Wealth Management's CRISPR Therapeutics position peaked at $3.2M in Q4 2020.
  • 498 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2021.

Based on Avitas Wealth Management's 13F filing for Q2 2021, filed 12 Jul 2021.